All In Biotech

Drug Trial Radar · NCT07007546

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single or Multiple Oral Doses of ABSK061 Mini-tablets and to Evaluate the Effect of Soft Food With ABSK061 Mini-tablets on Its Pharmacokinetic Profile in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

May 17, 2025

Primary completion

Jul 30, 2025

Study completion Apr 14, 2026

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
Jun 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To main objective is to evaluate the safety, tolerability, and pharmacokinetic profile of single or multiple oral doses of ABSK061 mini-tablets and to evaluate the effect of soft food with ABSK061 mini-tablets on its pharmacokinetic profile in healthy adult participants

Conditions

  • Healthy

Interventions

  • ABSK061Drug

    A total of 18 healthy participants were planned to be enrolled in Part I and randomized 1: 1: 1 to Sequences A, B, and C. Participants in three sequences received a single dose of ABSK061 at doses of 1 mg, 10 mg, and 35 mg.

  • ABSK061Drug

    A total of 12 healthy participants were planned to be enrolled in Part II, with multiple dose escalation trials prespecified in Sequences D and E, with 6 healthy participants in each sequence. In this MAD study, participants in Sequence D received ABSK061 microchips 5 mg QD(once a day) for 4 consecutive days.

  • ABSK061Drug

    Part III plans to include 12 healthy participants randomized 1: 1: 1 to Sequence F, Sequence G, or Sequence H to receive a single oral dose of ABSK061 in triplicate doses of Treatment 1, Treatment 2, Treatment 3. Treatment 1 is 5 mg ABSK061 taken with 180 mL of water, Treatment 2 is 5 mg ABSK061 taken with a spoon of yogurt (approximately 15 mL), and Treatment 3 is administered with 5 mg ABSK061 with a spoon of applesauce (approximately 15 mL).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics single-dose CmaxTime frame: Up to 48 hours post-dose
  2. Pharmacokinetics multiple-dose CmaxTime frame: Up to 24 hours post-dose
  3. Pharmacokinetics multiple-dose CminTime frame: Up to 24 hours post-dose
  4. Pharmacokinetics single dose TmaxTime frame: Up to 48 hours post-dose
  5. Pharmacokinetics single and multiple dose AUCTime frame: Up to 48 hours post-dose
  6. Pharmacokinetics multiple-dose RAUCTime frame: Up to 24 hours post-dose
  7. Pharmacokinetics multiple-dose RCmaxTime frame: Up to 24 hours post-dose
  8. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Initiation of study treatment up to 18-days post treatment
  9. Number of participants with abnormal laboratory tests results and abnormal physical exam findingsTime frame: Initiation of study treatment up to 18-days post treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangnan University Affiliated Hospital

    Wuxi, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.